KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Astrana Health (ASTH) EBITDA Margin (2016 - 2025)

Astrana Health (ASTH) has disclosed EBITDA Margin for 16 consecutive years, with 1.94% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 183.0% to 1.94% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2.47% through Dec 2025, down 192.0% year-over-year, with the annual reading at 2.47% for FY2025, 192.0% down from the prior year.
  • EBITDA Margin hit 1.94% in Q4 2025 for Astrana Health, down from 2.01% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 23.41% in Q3 2021 to a low of 1.1% in Q4 2023.
  • Historically, EBITDA Margin has averaged 6.96% across 5 years, with a median of 6.06% in 2024.
  • Biggest YoY gain for EBITDA Margin was 973bps in 2021; the steepest drop was -1348bps in 2021.
  • Year by year, EBITDA Margin stood at 1.15% in 2021, then surged by 271bps to 4.28% in 2022, then crashed by -126bps to 1.1% in 2023, then skyrocketed by 110bps to 0.11% in 2024, then soared by 1688bps to 1.94% in 2025.
  • Business Quant data shows EBITDA Margin for ASTH at 1.94% in Q4 2025, 2.01% in Q3 2025, and 3.11% in Q2 2025.